Stephen M. Broski, M.D.

Closed for Enrollment

• Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis Rochester, Minn.

  The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

• Evaluation of 18F-FDG PET/MRI and Whole Body MRI with DWI in the Evaluation of Multiple Myeloma Rochester, Minn.

  The purpose of this study is to compare the utility of whole body MRI (WBMRI) with diffusion-weighted imaging (DWI) and simultaneous 18F-FDG PET/MRI with time of flight (TOF) PET acquisition to identify and characterize osseous lesions in patients with multiple myeloma.

• Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients with Differentiated Thyroid Cancer (18F-tetrafluoroborate (18F-TFB) PET/CT) Rochester, Minn.

  The purpose of this study is to investigate radiotracer 18F-tetrafluoroborate (18F-TFB) for imaging of patients with differentiated thyroid cancer

   

• F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies Rochester, Minn.

  The objectives of the study are to determine the biodistribution of [18F]BF4 (TFB F 18 Injection) in patients with myeloma or endometrial cancer being treated with oncoviruses carrying the NIS reporter gene.

• Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients with Tumor Induced Osteomalacia Rochester, Minn.

  This study aims to identify cases of FGF23-mediated oncogenic osteoomalacia in which the underlying phosphaturic mesenchymal has not been found and perform 68Ga-DOTATATE PET in these patients to localize the tumor.